Foghorn Therapeutics Future Growth
Future criteria checks 2/6
Foghorn Therapeutics is forecast to grow earnings and revenue by 20% and 23.5% per annum respectively while EPS is expected to grow by 23.4% per annum.
Key information
20.0%
Earnings growth rate
23.35%
EPS growth rate
| Biotechs earnings growth | 23.7% |
| Revenue growth rate | 23.5% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 16 May 2025 |
Recent future growth updates
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 07
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target
May 09Recent updates
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Apr 09Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients
Mar 26Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 29% But Growth Is Lacking
Feb 23Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation
Feb 08More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 41%
Jan 01Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 07Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk
Oct 22Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up
Sep 01Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking
Jul 17Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target
May 09Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth
Apr 12Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too
Feb 22Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth
Dec 13Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues
Nov 07Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
Jun 14Foghorn Therapeutics: Selling For Less Than Cash Value
Oct 10Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286
Aug 23Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M
Aug 09Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
Jun 02We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely
Apr 13Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
Feb 27Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 41 | -89 | -90 | N/A | 7 |
| 12/31/2026 | 35 | -87 | -83 | N/A | 8 |
| 12/31/2025 | 30 | -77 | -81 | N/A | 7 |
| 3/31/2025 | 24 | -80 | -96 | -95 | N/A |
| 12/31/2024 | 23 | -87 | -101 | -100 | N/A |
| 9/30/2024 | 26 | -91 | -104 | -103 | N/A |
| 6/30/2024 | 35 | -86 | -110 | -110 | N/A |
| 3/31/2024 | 34 | -93 | -117 | -116 | N/A |
| 12/31/2023 | 34 | -98 | -119 | -118 | N/A |
| 9/30/2023 | 33 | -103 | -121 | -119 | N/A |
| 6/30/2023 | 22 | -115 | -114 | -112 | N/A |
| 3/31/2023 | 21 | -112 | -111 | -109 | N/A |
| 12/31/2022 | 19 | -109 | 192 | 194 | N/A |
| 9/30/2022 | 16 | -109 | 233 | 234 | N/A |
| 6/30/2022 | 9 | -109 | 233 | 234 | N/A |
| 3/31/2022 | 5 | -105 | 243 | 244 | N/A |
| 12/31/2021 | 1 | -101 | -54 | -50 | N/A |
| 9/30/2021 | 1 | -93 | -84 | -73 | N/A |
| 6/30/2021 | 1 | -85 | -65 | -50 | N/A |
| 3/31/2021 | 1 | -78 | -61 | -44 | N/A |
| 12/31/2020 | 0 | -69 | -47 | -31 | N/A |
| 9/30/2020 | 0 | -63 | -43 | -34 | N/A |
| 6/30/2020 | N/A | -58 | -52 | -49 | N/A |
| 3/31/2020 | N/A | -54 | -48 | -47 | N/A |
| 12/31/2019 | N/A | -51 | -47 | -46 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FHTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FHTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FHTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FHTX's revenue (23.5% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: FHTX's revenue (23.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FHTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/25 07:45 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Foghorn Therapeutics Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Gavin Clark-Gartner | Evercore ISI |